<code id='0FAE80FB41'></code><style id='0FAE80FB41'></style>
    • <acronym id='0FAE80FB41'></acronym>
      <center id='0FAE80FB41'><center id='0FAE80FB41'><tfoot id='0FAE80FB41'></tfoot></center><abbr id='0FAE80FB41'><dir id='0FAE80FB41'><tfoot id='0FAE80FB41'></tfoot><noframes id='0FAE80FB41'>

    • <optgroup id='0FAE80FB41'><strike id='0FAE80FB41'><sup id='0FAE80FB41'></sup></strike><code id='0FAE80FB41'></code></optgroup>
        1. <b id='0FAE80FB41'><label id='0FAE80FB41'><select id='0FAE80FB41'><dt id='0FAE80FB41'><span id='0FAE80FB41'></span></dt></select></label></b><u id='0FAE80FB41'></u>
          <i id='0FAE80FB41'><strike id='0FAE80FB41'><tt id='0FAE80FB41'><pre id='0FAE80FB41'></pre></tt></strike></i>

          
          WSS
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion